Arthritis Status Report Worksheet

Patient Name:			DOB::					
_		current regimen and no	changes	in treatment recommend	ed:			
	Yes							
	No							
	ir no, what r	ecommended changes:						
activitie	es?	ild to moderate sympto	ms with i	no significant limitations t	o range	e of motion, lifestyle, or		
	None							
	Mild to Moderate							
	Other, list limitations:							
Cause o	Psoriatic	l (limited to joint)						
	Ankylosing S							
	Osteoarthri							
		ell controlled?			Y Y	N		
	 No functional limitations? 					N		
_				nflammatory meds only?	Υ	N		
	Other cause	::						
	tion(s) - One or more of the following (check all that apply): Oral steroid – equivalent dose does not exceed equivalent of prednisone 20 mg/day NSAIDS Methotrexate Hydroxychloroquine/Chloroquine (Plaquenil/Aralen) – Mandatory Eye Status Report required* Any of the following? – (only one medication below is allowed with required no-fly time after each adalimumab (Humira): Adalimumab (Humira): Apremilast (Otezla): n/a							
		Etanercept (Enbrel):		4-hour no-fly				
		Infliximab (Remicade)	:	24-hour no-fly				
	Ц	Rituximab (Rituxan):		/2-hour no fly				
		Secukinumab (Cosenty	yx):	4-hour no-fly				
	Other:							
Labs:		ations, NSAIDS, or steroi , LFT, and Creatinine <u>wi</u>	-					
		tus Report included if n mal, please provide a co						
Treating Physician's Signature			Physician's Printed Name		Date			
			5 s.ut 5.1					

Expert FAA Medical Assistance!

Clinic Locations:

Wisconsin: 10520 W. Bluemound Rd, Suite 206

Milwaukee, WI 53226

Ohio: 7071 Corporate Way, Suite 105

Centerville, OH 45459

Mailing Address: 1817 Highland Dr. #1135 Grafton, WI 53024 Tel: 414-419-3300 Fax: 210-640-1938

HYDROXYCHLOROQUINE (HCQ)/ CHLOROQUINE (CQ) STATUS REPORT (Plaquenil/Aralen) (Updated 09/29/2021)

Name	e	Date of Birth Applicant ID# PI#								
MID#	Α	pplicant ID#	PI#							
			e this status report. The Airm AME or directly to the FAA:	nan must pr	ovide this					
	Using US Postal Service: Federal Aviation Administration Aerospace Medical Certification Mike Monroney Aeronautical C PO BOX 25082 Oklahoma City, OK 73125	n Division AAM-300	Using special mail (UPS) Federal Aviation Adminis Aerospace Medical Certi Civil Aerospace Medical 6700 S. MacArthur Boule Oklahoma City, OK 7310	tration fication Divisio Institute, Build evard, Room 3	on-AAM-300 ling 13					
1. Pr	ovider printed name/title:		Phone number		· · · · · · · · · · · · · · · · · · ·					
2. Da	Date hydroxychloroquine (HCQ) or chloroquine (CQ) treatment initiated									
3. Da	ate of most recent HCQ/CQ	screening	·							
4. Ty	pe of screening: □ Baseling	ne or □ Follow-up								
	Does the airman take or have ANY of the following:									
	Baseline evaluation includes: Eye evaluation with dilated fundus exam LOW-RISK May Consider CACI (NOTE: Will not require another exam unless or until airman meets any of the criteria in the gray box above.)	Group: A. HCQ/CQ medication for 5 or more yea. B. Tamoxifen or other drugs affecting the C. Renal Disease (GFR less than 60 mL D. Glaucoma E. Maculopathy and/or F. Higher than average renal weight dos HCQ > 5 mg/kg CQ > 2.3 mg/kg	e macula /min)	ith dilated fundus exi field* optical coherence CT) HIGH- Not CAC	am -RISK CI eligible SI/SC and					
	*Threshold visual field: 10-2 or 12-3 area is at risk (as determined by th Note: CACI/SI/SC is for Aviation Medio	e treating eye provider).	an descent, we will accept 24-2 or 30-2 threshold w	hen perimacular						
5. Ev	□ Yes	□ No								
	onormality on automated thr yes, explain:	□ Yes	□ No							
	onormality on Spectral-dom yes, explain:	□ Yes	□ No							
	8. Any other eye pathology, symptoms, color vision loss, or clinical concerns? If yes, explain:									
Treat	ing Provider Signature		Date D) guideline recommendations	_						